Ibuprofen/tobramycin/vancomycin Reactions 1680, p164 - 2 Dec 2017 Acute kidney injury: case report In a retrospective study of 243 patients, a patient [age and sex not stated] was described, who developed acute kidney injury during treatment with vancomycin, tobramycin and ibuprofen [not all indications and routes stated]. The patient, who had a history of cystic fibrosis and methicillin-resistant Staphylococcus aureus infection, started receiving treatment with IV vancomycin 20 mg/kg per dose every 12 hours. Subsequently, the patient showed an increase in serum creatinine from 0.71 to 2.26 mg/dL over a period of five days, which was suggestive of acute kidney injury. During that time, the dosage of vancomycin was increased to 20 mg/kg per dose every six hours. The patient continued on the increased dose for 48 hours. At that time, the patient showed serum creatinine level of 2.26 mg/dL [durations of treatments to reaction onset not stated]. The treatment with vancomycin was discontinued for three days. During that time, the patient had also been exposed to IV tobramycin at 800mg daily and ibuprofen at 600mg twice daily for three days. Later, the serum creatinine was normalised to 0.73 mg/dL. The patient was re-initiated on vancomycin therapy. Author comment: "This patient had multiple risks for nephrotoxicity, which reinforces that the use of chronic therapies such as ibuprofen in the setting of aminoglycoside and vancomycin should be avoided because of the increased risk of nephrotoxicity." Fusco NM, et al. Association of vancomycin trough concentration with response to treatment for acute pulmonary exacerbation of cystic fibrosis. Journal of the Pediatric Infectious Diseases Society 6: e103-e108, No. 3, Sep 2017. Available from: URL: http://doi.org/10.1093/jpids/pix043 - USA 803284131 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals


Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
Publisher site
See Article on Publisher Site


You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial